Precision-medicine platform for mild Alzheimer’s disease and at-risk individuals

“Alzheimer’s disease (AD) is a progressive, neurodegenerative condition in which individuals exhibit memory loss, dementia, and impaired metabolism. Nearly all previous single-domain studies to treat AD have failed, likely because it is a complex disease with multiple underlying drivers contributing to risk, onset, and progression. Keine et al. explored the efficacy of a multidomain therapy approach based on the disease risk factor status specific to individuals with AD diagnosis or concern. Their findings indicate previously unidentified connectivity between AD risk factors, suggesting that treatment regimens should be tailored to the individual, and should be multi-modal to simultaneously return risk factors to a normative state. If successfully performed, the possibility to slow progression of AD and even reverse aspects of cognitive decline may become achievable.”
Read the Full Story at www.eurekalert.org